Foram Vyas
A5052759766- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Phagocytosis and Immune Regulation
- Cancer Cells and Metastasis
- Single-cell and spatial transcriptomics
- Immune cells in cancer
- Cancer-related Molecular Pathways
- Metabolism, Diabetes, and Cancer
- RNA modifications and cancer
- Chemokine receptors and signaling
- Biochemical and Molecular Research
- Genetic and Kidney Cyst Diseases
- Liver physiology and pathology
- Autophagy in Disease and Therapy
- Cancer, Hypoxia, and Metabolism
- Pediatric Hepatobiliary Diseases and Treatments
- Cell Image Analysis Techniques
- RNA and protein synthesis mechanisms
- South Asian Cinema and Culture
- Sirtuins and Resveratrol in Medicine
- Mitochondrial Function and Pathology
Princess Margaret Cancer Centre
2020-2025
University Health Network
2020-2025
University of Toronto
2020-2024
Weatherford College
2022
Harvard University
2016
Intratumoral heterogeneity is a critical frontier in understanding how the tumor microenvironment (TME) propels malignant progression. Here, we deconvolute human pancreatic TME through large-scale integration of histology-guided regional multiOMICs with clinical data and patient-derived preclinical models. We discover "subTMEs," histologically definable tissue states anchored fibroblast plasticity, relationships to immunity, subtypes, differentiation, treatment response. "Reactive" subTMEs...
Abstract Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within COMPASS trial, patients proceeding chemotherapy for PDAC undergo tumor biopsy RNA-sequencing (RNA-seq). Overall response rate (ORR) overall survival (OS) were stratified by according received. Correlation with using gene profiling, situ hybridization (ISH) was explored. Results:...
The molecular drivers of antitumor immunity in pancreatic ductal adenocarcinoma (PDAC) are poorly understood, posing a major obstacle for the identification patients potentially amenable immune-checkpoint blockade or other novel strategies. Here, we explore association chemokine expression with effector T-cell infiltration PDAC.Discovery cohorts comprised 113 primary resected PDAC and 107 liver metastases. Validation 182 from Cancer Genome Atlas 92 PDACs Australian International Consortium....
Understanding cell fate regulation in the liver is necessary to advance therapies for hepatic disease. Liver progenitor cells (LPC) contribute tissue regeneration after severe injury yet signals instructing dynamics and are largely unknown. The Tissue Inhibitor of Metalloproteinases, TIMP1 TIMP3 control sheddases ADAM10 ADAM17, key NOTCH activation. Here we uncover role TIMP/ADAM/NOTCH/DLK1 axis LPC maintenance cholangiocyte specification. Combined TIMP1/TIMP3 loss vivo caused abnormal...
Abstract Integration and mining of bioimaging data remains a challenge lags behind the rapidly expanding digital pathology field. We introduce Hourglass, an open‐access analytical framework that streamlines biology‐driven visualization, interrogation, statistical assessment multiparametric datasets. Cognizant tissue clinical heterogeneity, Hourglass systematically organizes observations across spatial global levels within patient subgroups. Applied to extensive dataset, promptly consolidated...
Abstract Pancreatic ductal adenocarcinoma (PDAC) displays a high degree of spatial subtype heterogeneity. This intratumoral co-existence classical and basal-like programs is evident in multi-scale transcriptomic analyses resected, advanced-stage chemotherapy-treated specimens reciprocally linked to diverse stromal immune microenvironment as well worse clinical outcome. However, the underlying mechanisms heterogeneity remain largely unclear. Here, by combining preclinical models, multi-center...
Summary Pancreatic ductal adenocarcinoma (PDAC) remains resistant to most treatments and demonstrates a complex pathobiology. Here, we deconvolute regional heterogeneity in the human PDAC tumor microenvironment (TME), long-standing obstacle, define precise stromal contributions progression. Large scale integration of histology-guided multiOMICs with clinical data sets functional vitro models uncovers two microenvironmental programs that were anchored fibroblast differentiation states. These...
Abstract Pancreatic ductal adenocarcinoma (PDAC) has a complex disease pathobiology and poor treatment options, emphasizing the need for novel therapeutic targets. Hub genes have high connectivity (i.e., exceptionally many interaction partners), example, certain proteases with numerous partners. Thereby, hub are often central biological regulators dysregulated proteolysis is indeed key trait of malignant tissues. Here, we aimed to identify protease-related potential involvement in pancreatic...
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Supplementary Data from GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer